TGen to submit H1N1 test for emergency use
This article was originally published in Clinica
The Translational Genomics Research Institute (TGen) is to submit its H1N1 test to the US FDA under an emergency use authorisation (EUA). As well as detecting the flu virus, the test can identify the strain and discern whether it is likely to be resistant to the antiviral drug Tamiflu. It is the only resistance test available that uses a standard molecular technique to make exact copies of components of the H1N1 virus' genetic material, the Phoenix, Arizona-based non-profit organisation claims. Currently, only the US Centers for Disease Control and Prevention (CDC) and "a few select labs" can look for resistance, it added. TGen developed the test with molecular diagnostic firm PathoGene.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.